B2BROKER Group Puts AI at the Core of B2TRADER as Technology Enters a New Era WatchGuard’s New Mid-Range Firewalls Deliver the High Performance for Organisations to Protect Against Encrypted Malware
New Firebox M Series combines security, performance, flexibility and visibility for the WatchGuard Unified Security…
360° Mounting: Reader with a Special Twist
Elatec Receives Patent for USB Rotary Connector Munich – Elatec’s TWN4 USB Front Reader makes…
83% Will Have Deployed Wi-Fi 6/6E by 2022
WBA cross-industry survey of service providers, technology vendors and enterprises demonstrates mass adoption of Wi-Fi…
Asian Football’s First-Ever NFT Auction Launches 12 October 2021
OliveX and Hong Kong Premier League’s RCFC in Ground-Breaking Innovation for the Region 5 October…
Orphazyme provides regulatory and financial updates
Orphazyme A/SCompany announcement No. 22/2021Company Registration No. 32266355 Copenhagen – October 5, 2021 – Orphazyme A/S…
Orion publishes Interim Report for January–September 2021 on Wednesday 20 October 2021
ORION CORPORATION PRESS RELEASE 5 October 2021 at 9.00 EEST Orion publishes Interim Report…
OXURION to Present at the Lytham Partners Fall 2021 Investor Conference
Leuven, BELGIUM, Boston, MA, US – 5 October, 2021 – 08.00 AM CET –…
Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis optica spectrum disorder at ECTRIMS 2021
OCREVUS (ocrelizumab) data to show sustained reduction in disability progression through 8 years for primary…
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
Potential Indication Expansion for Telix’s Core Kidney Cancer Theranostic Program MELBOURNE, Australia and LIÈGE, Belgium, Oct. 05,…
Biophytis Announces the Drawing of 2 New Tranches of ORNANE Under the 2020 Atlas Contract for €6 Million
PARIS and CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) — Biophytis SA (NasdaqCM: BPTS, Euronext…
IN8bio to Present at BioFuture 2021 and Advanced Therapies Congress & Expo 2021
NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical…
Nabriva Publishes Data Demonstrating the Potent Anti-Inflammatory Properties of XENLETA® (lefamulin)
DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc…
T2 Biosystems Announces BARDA Exercise of Contract Option 2A Valued at $6.4 Million
Advances Development of Diagnostics for Sepsis-Causing Pathogens, Antibiotic Resistance, and Biothreat Pathogens LEXINGTON, Mass., Oct….
ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase…
Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
Continuing filgotinib 200mg among induction non-responders at week 10 resulted in clinical benefits for ulcerative…
CorMedix Inc. Announces Executive Leadership Changes
BERKELEY HEIGHTS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical…
Progenity Announces $20 Million Registered Direct Offering of Common Stock Priced at Premium to Market Under Nasdaq Rules
SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative…
NanoZolid®-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that no further patients will be enrolled…
Valneva Announces the Cancellation of Ordinary Shares Held by the Company following Termination of its Liquidity Agreement
Saint-Herblain (France), October 4, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty…
AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)
PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO START CLINICAL…